Saturday, May 23, 2009

Body Shape Changes Dramatically Impact the Self-Esteem of HIV-Positive People


BBody Shape Changes Dramatically Impact the Self-Esteem of HIV-Positive People

An Interview With Nelson Vergel

April 15, 2009

Multimedia Options

Listen to Audio (27 min.)

Please note: These files can be quite large. Allow some time for them to download.

Hi there! This is Bonnie Goldman, editorial director of TheBody.com.

Today we're going to take a look at body shape changes, an ongoing problem for many people living with HIV. These changes are sometimes known as lipodystrophy, lipoatrophy or lipohypertrophy, but they all involve the same thing: An unusual amount of fat loss or fat gain in specific parts of the body. Some people with HIV have watched their face, legs, arms or buttocks transformed by fat wasting. Others have seen the growth of fat deposits on their backs or necks. Men and woman alike have even watched their breasts swell due to this problem.

These physical changes are relatively well known. But there's another side to body shape changes that receives much less attention: the emotional side. That's what we're going to talk about today: the impact that body shape changes have on the everyday lives of people with HIV.

This podcast is a part of the series "HIV News & Views." To subscribe to this series, click here.
I have with me today Nelson Vergel, a longtime AIDS activist and 26 year survivor of HIV. He runs a popular HIV/AIDS e-mail mailing list and is a frequent speaker at workshops across the country. He has been witness to the emotions tied to these often disfiguring body shape changes, and he's watched the desperation escalate as the years pass without any solution.

Last year, Nelson created an anonymous Internet survey that asks people with HIV to detail the impact of body shape changes on their quality of life and self-esteem. The survey results were presented at a major medical conference in London last fall. I am pleased to have Nelson here today to discuss his survey and the rather troubling results.

Nelson Vergel, B.S.Ch.E., M.B.A.

Nelson Vergel, B.S.Ch.E., M.B.A.

Welcome Nelson!

Hi, Bonnie. Thanks for having me again.

I thought today would be a great moment to talk with you about the poster that you presented at an international conference that was held in London, I believe.1

Yes, in London. The conference was the 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, which was held this past November.

You are an activist. Isn't it unusual for an activist to present a poster at a medical conference?

Yes, but only because very few activists are aware that we can conduct, and present posters on, socially related studies. My background is chemical engineering and I have an MBA, so I have no real medical background. However, I wanted to do this survey, because no one had conducted an in-depth survey of what people are going through with respect to body changes in HIV.

We've had some studies -- small ones -- where questions about this were asked. How do you feel? Is this depressing you?

They showed that people were experiencing stress, anxiety, low self-esteem, etc. But I wanted to dig deeper into the issue, so I posted a 23-question survey online and The Body actually helped me out a lot by getting the word out. I had 1,100 people answer the survey in a matter of six months. The poster was presented to show the results of that survey.

So you did this survey to meet an unaddressed need?

Yes, my feeling as an activist is that we're moving away from lipodystrophy research. No one is addressing the lack of reimbursement for facial wasting treatments, hump removal or liposuction. We're having a lot of trouble getting these options reimbursed by Medicare, Medicaid, insurance companies and patient assistance programs. So I wanted to let researchers know that this problem is not gone. A lot of patients are suffering from this problem and they're not getting reimbursement and coverage of the therapy.

It's not only a reimbursement issue. Isn't it also a huge emotional issue?

It's extremely emotional. I've been positive for 25 years, and nobody wants to look sick. Nobody. Even if we are not feeling very well. I hate when I go to work and people say, "Oh, you don't look very good." I don't want to hear that or, "What happened to you? You look tired. Are you losing weight?" Everybody wants to look healthy. So yes, it's a huge emotional issue.

Don't you think it's more than just looking sick?

It's also looking older than you are. Looking unattractive. It's being afraid to go out and show your face. Being afraid to go back to work, if you're on disability. Being afraid to be found out that you're HIV positive, if you're in the closet about it. There are many, many issues. This is an issue especially for the many HIV-positive people who are in the entertainment field, hotel management and other professions that require dealing with the public.

The most surprising thing in this survey is that out of 1,100 [At the time the survey was presented at the London conference, only 949 need people had answered. Since the presentation, 1,100 people have responded.] Of the people that answered, 25 percent of them had thought about suicide in the past. Forme, that was shocking. The survey also showed that 87 percent of the participants experienced anxiety and depression related to body changes.

That is very shocking. Don't you think part of that pain is due to the general lack of acknowledgement by HIV doctors regarding what HIV-positive people are going through in terms of losing fat in their faces or legs? Some doctors just say, "OK, well just take your pills then."

They don't really say that, because doctors know better. Instead, they say, "Look how well you're doing. Your CD4s are up. You're undetectable. You're alive now."

I have to say, many doctors are really trying hard to educate themselves on lipoatrophy and lipodystrophy options. They really are.

To be honest with you, I don't think we're doing enough to educate doctors about patient assistance programs and about where to send patients when they bring up the issue of facial wasting, a big belly, buffalo hump or enlargement of the parotid glands [the largest of the salivary glands], which when inflamed can be visible as swellings on the sides of the face.

It's not as if doctors don't want to help. A lot of doctors are not educated on the subject, because there haven't been good efforts to train them beyond what we know about tenofovir [Viread] not causing lipoatrophy as much as d4T [Zerit, stavudine] or AZT [Retrovir, zidovudine].

Doctors do not know what options are available to patients with body changes and who is paying for them. They need to be educated about that. So that's my goal, not only via this survey, but also through my Web site FacialWasting.org. I have a list of doctors who are doing different things. And I know The Body has done a great job with its Lipoatrophy Resource Center. You probably are the only ones who have that on the Internet. Yet, we have to do a lot more work on showing resources to people. How do you apply to a patient assistance program to get help with your payments? What are the options out there? Doctors don't really know.

I think it is time to set up lectures and seminars to educate doctors, so that when the patient says, "Look at my face. Look at my belly. Look at my veiny legs. Look at my butt. I can't sit for more than 10 minutes without hurting. What can I do?" The doctor can say, "Look at this table of options," "Call these people," or "Here's a referral."

That's what I want to do.

A lot of people think that this is an old issue. They think that people who were diagnosed in the last couple of years are not going to have this experience and so we don't have to talk about it anymore.

It's almost like we're dinosaurs about to become extinct, you know? [Laughs.] That's an excellent point. If you were recently infected, or were infected in the past four years and you started medications in the past three years, you're probably going to have less of a problem, because doctors are not prescribing the main culprits of facial lipoatrophy and body lipoatrophy, which are Zerit and AZT (this drug is also present in Combivir).

Crixivan [indinavir] causes some problems with insulin resistance and belly fat, but it is also no longer prescribed in the U.S. So yes, your chances of experiencing lipoatrophy are going to be lower, but I'm still hearing from recently diagnosed people taking Atripla [efavirenz/tenofovir/FTC], or a very, very lipid-friendly combination, that are experiencing body changes.

A study done by the ACTG [AIDS Clinical Trials Group] actually showed that 11 percent of people taking tenofovir, 3TC [Epivir, lamivudine] and Sustiva [efavirenz, Stocrin] experience lipoatrophy. That's 11 percent of people who have never been exposed to AZT or d4T, so there is a minority of patients thatmay have lipoatrophy even though they have never been exposed to the main culprits of this problem.

Isn't it true that we still don't really understand how or why body shape changes are happening?

Not yet. We don't have all the answers. We don't even have what we call a "case definition," meaning researchers and clinicians have not agreed on how we are going to define this syndrome. Actually, it'snot a syndrome. It's a combination of syndromes and that's what makes it even more difficult to classify for insurance companies and Medicare. "What is this? What is this diagnosis?"

Now, tell me about your survey.

Impact of Lipodystrophy on Quality of Life and Self Esteem Survey Questions

The survey included mostly white patients who are over 40 years old that have been positive for more than 15 years. Unfortunately, not many Latinos like me, black people, American Indians or Asians took the survey. Also, most of those who responded were male. Maybe more males were exposed to the drugs that caused facial wasting. Or maybe more males are accessing the Internet.

Remember, this survey was only available on the Internet, so it was skewed in that way. And the participants had been positive for around 15 to 20 years. I would say 20 to 30 percent have been HIV positive for more than 20 years, which makes me feel a little good because I usually feel lonely being a long-term survivor who has had HIV for 25 years. Out of 1,100 [people, 275 were living with HIV for more than 20 years.

Eighty-four percent of these men and women were exposed to Zerit, for example. Of course, many of them are experiencing lipoatrophy, facial wasting and all that. Eighty percent of participants were exposed to AZT. Fifty-one percent had taken Crixivan, which is another drug that has been implicated insome of these problems.

My survey is a little bit biased since it includes so many long-term survivors who have been exposed to a lot of these old drugs. They have experienced more problems with body composition and body changes.

Will this happen to newly diagnosed people who are taking Atripla? I don't think it'll be as big of a problem. We do have to still research what's happening to those 11 percent that I mentioned before, but at the same time there are thousands of us.

Out of 1.2 million people in the United States who are HIV positive, around 450,000 are taking medications. Out of those, maybe half, probably more have been exposed to HIV medications for over 10 years. So there are around 250,000 people that may have somebody changes in this country.

Yes, we are the older generation. Yes, we need help. I hear clinicians say, "Our research is more focused now on insulin resistance and metabolic syndrome." I keep reminding them that we need to deal with fat accumulation. Nobody has a real good answer about why our bellies increase. Even in the new studies with Atripla, we see fat increase in the visceral area (in the organs area). So belly fat accumulation is still happening.

What we're not seeing as much is lipoatrophy, which is fat loss under the skin. We're not seeing as much of that, but we're seeing fat accumulation. We're seeing muscle loss too that is not being researched.

So Nelson, your survey attempted to describe the problem in greater detail.

Yes. What are people suffering from? What are the needs out there? It is a biased sample, because it did not include that many people who were infected under five years ago.

I'm going to tell you something else. I asked the question, "What kind of body changes are you experiencing or have you experienced?"

  • Sixty-three percent of them said belly fat gain.
  • Seventy-eight percent said facial wasting.
  • Seventy-two percent said butt wasting.
  • Sixty-eight percent said veiny legs and arms.
  • Twenty-two percent said increased breast size -- some women and men can have an increase in their breast tissue.

So, as you can tell, most of them have experienced some changes and they're pretty severe.

Impact of Lipodystrophy on Quality of Life and Self Esteem Survey Questions

To the question: "Have you experienced depression or anxiety due to the body changes?" Eighty-eight percent said yes. Eighty-eight percent. This is notvanity. People have said, "Get over it. We're older. We're not ever going to look as good as we used to."

This is bullshit. I tell people that when you look 20 years older than you are, when you look like you are going to die, when you look like you are sick, or when you have 300 to 400 T cells, you worry. Of course you do. Probably the most important question I asked people was, "What has changed in your life because of this?" The number one answer: 74% said decreased sexual activity. Number two was stopped socializing and going out to meet people.

People are feeling so self-conscious. They're not going out to meet new people and, obviously, they're not having as much sex, because they're afraid to be rejected or they are being rejected for their looks.

  • Fifty-one percent said they had stopped dating.
  • Sixty percent said they "worry too much about people finding out they are positive."
  • Fifty-seven percent said they stopped looking at themselves in the mirror. They probably just comb their hair in the morning; When we were young, you remember how many times we used to look at ourselves in the mirror?

So a lot of self-esteem issues?

Yes. Most change their clothing style, wearing more baggy clothing to hide bellies. Thirty percent said they have depleted their money in search of a solution.

Then I asked them in this survey, "What have you done to try to reverse your body changes?" Obviously, the two top things people say are, "I'm exercising more," 73 percent, and "I'm watching what I eat," 72 percent.

Fortunately and unfortunately, we have very few studies -- tiny, tiny studies -- on exercise that haveshown some benefits in body shape changes. With exercise we have seen decreases in visceral fat and increases in muscle mass. Actually, I think exercise therapy should be a therapy in HIV and should be reimbursed as such. That's one of my activist goals.

Many people mentioned that they watch what they are eating because of their body shape changes. Unfortunately, we only have maybe two studies -- very tiny cohorts -- that show that there may be some influence with respect to what we're eating, but not really. We're not seeing that dramatic of a difference by decreasing carbohydrates.

Actually, there's not a single well done study that shows whether or not, for instance, we will have any improvements in visceral fat if we decrease our carbohydrate intake. Nobody has done that study and it makes sense to do it.

What else? Forty-one percent of the people who took the survey said that they had had their face injected with a filler or a cosmetic product, which is probably what most people would like to do, because there are some options like Sculptra [an injectable product made of poly-L-lactic acid; also known as New-Fill] and Radiesse [a dermal filler made of calcium-based microspheres suspended in a water-based gel] in the United States that have patient assistance programs.

Forty-five percent took supplements even though we have no data whatsoever on supplements. Forty-seven percent took testosterone, though there could be many reasons for that. Maybe people had a low sex drive. But testosterone has been shown to decrease waist size in one ACTG study, in which a one-inch decrease in waist size was seen, though it was mostly fat under the skin, not visceral fat that went down.

Some people have used growth hormone. Some people have used anabolic steroids. Very few people undergo liposuction.

A hot subject for a lot of people was butt implants. People are getting their buttocks fixed, but very few can afford that, because it's a lot of money and you have to go to Mexico or Canada for the procedure. It's only for the few that have over $6,000 to spend. Some people are using padded underwear. That's a really cool option. It only costs $25. [For a list of suppliers for butt enhancers, visit TheBody.com'sLipoatrophy Resource Center.]

People think it's cosmetic, it's superficial, it's narcissistic. It's really not. People just want to look normal and they want to feel comfortable.

I've gotten some work done down there too. I usually try something before I talk about it, but I may not be as poor as most people. Unfortunately, more than 60 percent of HIV-positive individuals in the United States are on Medicare or Medicaid.

About the butt, it is painful to sit when you have wasting there. When I go to give lectures, a lot of people, ask me, "What kind of chairs will you have? I'm hoping you will have some padded chairs, because it really is painful."

I think whoever comes up with an option for buttock wasting will make a lot of money in this country. Why? Because buttock wasting is related to functional capacity and pain. Anything related to pain can usually get better reimbursement from every insurance company. It may be perceived as cosmetic, but it is a pain-related issue.

Something else I wanted to bring up is an option for belly fat (lipohypertrophy). A company in Canada, EMD Serono, is doing research on a growth hormone precursor that has shown some good results: a 13 percent loss in 26 weeks. I don't think it's great, but I think it's OK.

It's called tesamorelin and it's a product that you inject under the skin in your belly, a lot like growth hormone used to have to be. But the good thing about the drug is that it does not cause, supposedly, side effects such as increased blood sugar, body aches and carpal tunnel syndrome like growth hormone used to. It may, and I think it probably will, get approved in the United States within a year. [For more on tesamorelin, click here.]

I think we're going to see a lot more awareness of lipohypertrophy once this product is approved and marketed to doctors.

My concern is that it will probably be conceived as another cosmetic product by Medicare, Medicaid and insurance companies and it may not be covered or reimbursed. Daily injections will probably be very expensive. We'll probably face the same struggle we're having right now trying to get insurance companies to pay for facial lipoatrophy options like Sculptra, Radiesse or even Silikon microdroplets. (By the way, you can find more information on my Web site FacialWasting.org. )

I would say the rejection rate for reimbursement is probably 90 percent. Only the HMOs [health maintenance organizations] like Kaiser, and sometimes even the VA's system [U.S. Department of Veterans Affairs], have it in their formulary. So we're seeing some progress, but not big enough. I'm trying to get experts, third-party payers, activists, the FDA [U.S. Food and Drug Administration] and people from different companies to sit down at a roundtable to come up with a plan regarding how we can change policies to include HIV-related body changes as a clinical condition that requiresreimbursement.

Some doctors from Brazil presented a poster at the International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV where they show that the government has implemented a countrywide program that pays for various lipodystrophy (e.g., facial wasting and belly fat accumulation) treatments, such as liposuction. Canada offers some help too, as do The Netherlands and many countries in Europe. So we're lagging behind. It's been 11 years since lipodystrophy was first mentioned. It is time to do something about it.

Talking to the point of who's going to pay for these treatments, 62 percent of people in your survey had to pay for it themselves. What was encouraging was that at least 18 percent had insurance to pay for this.

Yes, that's good. It's actually not as discouraging. Eighteen percent of people found insurance companies to pay for whatever they used. But 62 percent had to pay for it out of their own pocket. And to get your face fixed with Sculptra or Radiesse, if you have moderate to severe facial wasting, it costs around $7,000 to $8,000 easily.

Is there a patient assistance program?

There's a patient assistance program. If you make under $40,000 a year, you can get full coverage for the Sculptra, but you still have to pay for the doctor's fees to inject it in your face. Most doctors charge around $350 to $400 per session and most people require at least four to seven sessions, because it is not a permanent product. It's a product that builds up slowly in your face and then some people need touchups a year later.

For Radiesse, there's also a patient assistance program. They have a discount for people that make less than $40,000. [Very few people know about Radiesse. Radiesse is another product that has shown very good results. It probably lasts a little longer than Sculptra. You need also at least four sessions for that.

So there are two products that are approved in the United States: Sculptra and Radiesse. Both have patient assistance programs and you can find out more online. Sculptra.com has a list of doctors in every ZIP code that have been trained -- and Radiesse does too.

There's another option called Silikon microdroplets. It is permanent. It takes also around four sessions, but it's not covered or reimbursed, because it's not approved. It's used off-label.

You've described the problem and you showed that most people are paying for treatment by themselves. Most people are very concerned about this issue and the survey was presented at an international conference. What's the next step?

I think we need to do a few things. We need to increase awareness that this problem hasn't gone away. We need to, as I said, set up a brainstorming or roundtable discussion that includes the main players -- not only the patient community and activist community, but also doctors, researchers that work in lipodystrophy, people from Medicare and Medicaid, and people from third-party payment companies -- to put together some kind of plan.

Do we need more data? What are the CPT [current procedural terminology] codes that actually get reimbursement? There are some out there, but they're not well defined.

How can we convince insurance companies that this is not only a cosmetic issue? That this is a clinical issue that impacts quality of life and can result in depression, anxiety and even suicidal thoughts. It even impacts adherence; some studies have shown that adherence tends to drop when people are very afraid of their medications and body changes.

I foresee this booklet that we all put together with recommendations that then affects a policy change. I would love to see a bill passed by Congress.

With breast cancer, they had to do this too and they passed the bill so that after a mastectomy, breast reconstruction is covered by private and public insurance. I want to see an HIV lipodystrophy reimbursement bill in two years, no longer than that. It will take a lot of work. Hopefully, we have a better administration in Washington, D.C. So that's what I want to see, but we have to start with some kind of document.

A lot of people listening to this have been feeling desperate. And now that they're hearing this, I imagine they're feeling very hopeful. Is there anything that people listening to this can do to help you?

They need to e-mail me. My e-mail is NelsonVergel@yahoo.comNelsonVergel@gmail.com,NelsonVergel@aol.com. It's very easy to remember. Just write to me and let me know you want to help. I have to tell you, Bonnie, and I'd say that this is the most disturbing thing that I've learned, there's an 80-20 rule in everything in life. When there is a problem, 80 percent watch while 20 percent do something about it. Eighty percent of people complain and bitch and moan and are depressed, and yet, they don't think they have the power to make a change.

They think they're too small to make a change. They think their voice doesn't count. But you know what? In the U.S., writing a letter to Congress (or to your representative or senator) -- you could even pick up the phone -- if that's all you did, you did a great thing. [Use these links to contact your representative.]

We need to empower people to know that there's something they can do. I read this book The Tipping Point -- we need to get to a tipping point in this problem where there are so many people complaining to their congress people that a bill is passed. I really think we need a bill and I think we can do it.

It sounds like you're energized and you just need people to help you.

Yes, I need people to know that they're not little. They are not small. That they are powerful.

Know that without leaving your house, you can do a lot. You can write letters. You can call. You don't have to leave your house.

I think people want concrete things that they can do, because they don't necessarily know what to do.

Yes.

You can either write about your case or you can write about a friend's case. Anybody that can vote for a seat in Congress can complain about something, even if you're not directly suffering from it. You don't have to have lipodystrophy, by the way, to help us either. You don't even have to be HIV positive. So, e-mail me. I'm trying to come up with that formatted letter that people can send to their representatives.

This has been really interesting, Nelson. I think this is the beginning of hopefully getting this covered by insurances and getting more attention paid to this issue.

Yes, because we only get what we deserve. If we're not doing enough to change something, then we don't deserve the change. So I tell people, if you think you really deserve somebody to take care of this for you, you need to get involved, because otherwise you don't deserve the change. Unfortunately, there are a lot of us that may be tired or depressed. When you're depressed or have anxiety, as I think a lot of people do in this case, you don't feel like picking up the phone, you don't feel like writing a letter. So I understand that too. It's very hard to be empowered when you're depressed.

It's particularly hard to feel empowered when you have a stigmatized disease. There are layers of issues that are difficult to deal with.

Yes. We haven't even talked about the other problems related to metabolic disorders, such as bone density loss. Some of us are losing bone density. Some of us have diabetes and insulin resistance. Lipodystrophy is not the only body issue that we face. There are lots of issues internally that are happening: fatty livers and stuff like that. Those are all a part of this syndrome, and should also be discussed.

I would suggest that if you haven't visited the lipoatrophy resource center of The Body, read the information there. It's great. There are videos. There are patient testimonials. There are resources.FacialWasting.org is one of my Web sites. You can always e-mail me. You can always ask me questions in my nutrition and exercise section of the "Ask the Experts" forum.

In addition, I have a group called Poz Health at Yahoo Groups that has 3,000 members that discuss these things too. The Body also has a place you can connect with others, so you are not alone.

I tell people, "You are not alone." If you are home worrying about this, you are not alone. There are maybe 250,000 of us who feel just like you. Connect with those people, network with those people, because you're not little. You're powerful. Even if you are feeling depressed, even if you are afraid of disclosing, you still are powerful. We need to get this done.

Thank you, Nelson.

This transcript has been lightly edited for clarity.

Take Nelson's lipodystrophy survey and share your experience with body shape changes.
View the slides for this survey.
View the comments for this survey.

Reference

  1. Vergel N. Impact of body changes on the quality of life of HIV-positive treatment-experienced patients -- an online community-based survey. In: Program and abstracts of the 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; November 6-8, 2008; London, United Kingdom. Abstract P-67.

Nelson Vergel: Going Beyond Survival

A leading advocate’s thoughts on getting the most out of life
by Jeff Berry

In 1986 Nelson Vergel was only 27 years old when he learned he had HIV. At the time, he wasn’t sure he’d make it to 30, let alone to one day see 50. At the recent Retrovirus conference in Montreal in February, he invited a large group of friends to dinner to share his fiftieth birthday with him.

“Being 30 was a big milestone, 40 was a huge one, and now 50…I never even thought, three or four years ago, I was going to be 50,” says Vergel. “It was a big miracle for me, which I was able to enjoy with my friends.”

A native of Venezuela and former chemical engineer, Vergel is a 25-year survivor of HIV who has, by necessity, become a leading treatment advocate for people with HIV. Vergel has developed multi-drug resistance (MDR), rendering his HIV essentially resistant to every commercially available HIV drug, but you’d never know it by looking at him. Vergel is the picture of perfect health—fit, toned, and tanned—and even though on disability, probably works harder than most people with a full-time job. And while he claims he’s dealing with it, he says it sometimes makes him feel like he’s not going to live that much longer. “Yet,” he laughs, “I’ve been around forever.”

His number one issue right now? “Fatigue,” says Vergel, without hesitation. “People think I’m a hyperactive person, I lecture around the country, and yet when they see me is when I’m at my best. I would say that 80% of the time I’m struggling to get to the point where I have enough energy. I have severe fatigue—it’s cyclic, it comes and goes—but most of the time I have it, and I have to find ways to deal with it.”

Vergel, an international speaker on HIV treatments and side effect management, and co-author of the book Built To Survive, says that the people who come to his lectures are aging and long-term survivors who, like himself, experience fatigue, as well as gastrointestinal (GI) problems. “We used to blame Norvir—well, I haven’t taken Norvir for three years, and I still have some diarrhea and bloating, so that’s my number two,” jokes Vergel.

“I’m 50 years old, I exercise, I look pretty good, and I try my best to keep my body in shape and not fall apart with lipodystrophy or wasting. But at the same time, I wonder if this is the way a healthy 50-year-old feels. And I’m almost sure that the answer is no.”

Vergel says he is on a constant search for the answer to fatigue, through research, reading and consuming HIV information on a daily basis—to the point where it’s almost become a full-time job. Curiously enough, a recent e-mail from HIV advocate Jules Levin, founder of the National AIDS Treatment Advocacy Project (NATAP, see article on page 36), gave Vergel his first glimpse into why some people with HIV are experiencing so much fatigue.

“They conducted a study where they performed functional MRIs of the brain, and they found a section of the brain that, when compared to healthy HIV-negative subjects, produced less creatine, which is a metabolite for energy production. So already there’s something going on in our brain that is causing us to have fatigue. Some people also blame, of course, side effects of medications we’re taking. Fatigue is occurring not only in people like me who are dealing with MDR, but it’s also occurring in people with undetectable viral load. So I’m always searching for ‘What is it?’ and ‘How can we treat it?’ ”

To treat it, Vergel takes testosterone by injection every two weeks, which keeps his testosterone hormone levels within normal range. He also takes vitamin supplements, including B vitamins, for the reason that B-6 and B-12 deficiencies have been correlated to fatigue.

“Another drug that’s becoming popular is Provigil [modafinil],” says Vergel, “It’s actually been studied in people with HIV at Sloan-Kettering in New York, with great results.” He cautions, though, that the drug is metabolized through the same P450 pathway in the liver which many HIV drugs use, and therefore more drug-drug interaction studies are needed. Vergel states, however, that many are now taking Provigil once or twice a day to battle fatigue and depression.

“I tell them we have to go beyond getting our T-cells up and getting our viral load down to undetectable.”He said doctors have also been prescribing Adderall, which is a stimulant composed of mixed amphetamine salts, and is thought to work by increasing the amount of norepinephrine and dopamine in the brain. It’s used to treat Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy (a chronic sleep disorder), but, on the downside, it may become habit-forming.

“There’s green tea, and some people take ginseng— I’ve tried that too,” says Vergel. “So there are some of us in this constant search for what we call a pseudo-normal life, either through medications or other things to increase our energy level, because without energy, there’s no life. When I’m tired, not only do I not produce, I don’t write, I don’t help others, I feel depressed, everything collapses. I cannot deal with stress, I don’t want to pay my bills, I’m too tired for that, or to deal with phone calls. So energy and fatigue really, really affect everything in life, even adherence—but we need more studies.”

Another big issue, says Vergel, is undiagnosed sleep apnea, which he has a mild case of. He says that some of us wake up more tired, sometimes, than when we went to bed. But according to Vergel, most people are not referred to sleep labs, because many doctors feel that if you’re HIV-positive, you’re expected to feel fatigued. Some individuals may have sleep disorders that are either induced by weight or by things they aren’t even aware of, including side effects from drugs such as Sustiva or Atripla, which may be causing a disruption in their sleep patterns.

“It’s really important that all of us, even those who are HIV-negative, deal with the acceptance of aging.”It’s often a struggle, says Vergel, to have a really good quality of life. “I tell people that survival doesn’t mean anything unless you have a good quality of life. I mean, if you’re going to stick around in this world, and yet you’re tired all the time and you’re depressed, your body’s falling apart, and you’re actually not keeping yourself in good health, then what’s the point, really, of surviving? I tell people that we have to go beyond survival.”

And it just so happens that going beyond survival is the subject of Vergel’s next book, which he says is two-thirds complete and due out later this year. It’s a compilation of 25 years of what he calls “collective health wisdom,” which is a tremendous amount of information he has learned while moderating his list serve (pozhealth at Yahoo! Groups) as well as from e-mails he’s received from people with HIV all over the world.

“People ask me, ‘How do you know so much?’ ” says Vergel. “I’m reading e-mails from other people who’ve tried different things. There’s this collective wisdom that we have as long-term survivors. I think we also know a lot in HIV as we age, more than any other disease, we’ve learned so much and, yes, we keep it to ourselves and it’s time to share that. For instance, what we have learned about hormones, we’ve been using them for 20 years, before anyone else did; what we have learned about exercise; what we have learned about nutrition, supplements, things that help with energy, depression, and sexual function—that’s something nobody wants to talk about.”

Vergel says he sees the younger generation of HIV-positives only worrying about taking their pill and moving on with life and while he thinks that’s good, he tells them to go beyond that. “Thinking about HIV all day isn’t very good for you anyway,” says Vergel. “I tell them we have to go beyond getting our T-cells up, getting our viral load down to undetectable—there are other issues that come up. We’re now having concerns about bone density. We seem to be losing bone more than healthy people—are we going to have fractures in a few years? And most of us are taking Truvada or Viread—is it really going to end up affecting our kidneys? Our liver—some of us, like myself, have hepatitis B or C—is cirrhosis going to affect us at the end? I wonder about liver, kidney problems, bone density—and there are bigger issues that I think are coming up in most studies, such as cancer, including anal cancer. They say a little education is needed for doctors and patients about how to diagnose problems that lead to anal cancer; how to catch it early; Pap smears—what does that mean? Should we all be getting that?

“People say, ‘You’re so obsessed with health.’ Well, I’m obsessed with life! I want to live a good life! I love my life. I think having a good quality of life so that I can travel and lecture is very important, so I have to be aware of all these things. Are we going to have a shitty older life? I don’t know, I don’t think so. Maybe some of us are, some of us may not—some of us may reach a very healthy 80-year-old age. I think some people forget that, people with HIV, yes, we may have more health issues, but we also go to the doctor 10 times more frequently than any other person out there. We go to the doctor every three months—they check our lipids, they check our blood sugar, our kidneys, our liver, chemistry, all that. Very few people in this country go to the doctor every three months. Most Americans don’t go to the doctor for years, until something happens to them. So yes, we may have some issues, but we keep an eye on them more than anyone else, so that’s a good thing. It makes us a little bit more, I won’t say obsessed, but focused, on numbers than anyone else. Are we sicker than most people? Maybe, maybe not. But we’re definitely being monitored more frequently than any other people in the United States.”

Vergel says it breaks his heart that a lot of the younger folks who come to his lectures are completely clueless. “There is this vast amount of information we have as a community, and yet we weren’t able to really package it so that we could say, ‘Here—read this, and hopefully you’ll learn what a lot of us old folks have dealt with. Without scaring them, of course—I don’t want to scare the new, naïve patients because, as I said, they’re going to have it easier than we did. They have drugs that are a lot more friendly and don’t cause lipodystrophy or lipoatrophy, and they don’t have to take high doses of Norvir anymore. But yet, I think they’re going to have issues—they may not be as severe as ours, but there will be things that probably bother them, like CNS problems with Sustiva, some bone density issues, some kidney toxicity eventually, or even cancers that may flare up later in life.”

The stigma associated with being HIV-positive is a continuing problem, admits Vergel, which contributes to feelings of loneliness and depression, especially in older adults. While he doesn’t see it going away any time soon, he does believe there’s reason to hope.

“Women with HIV who are heterosexual, they’re stigmatized horribly,” he says. Vergel goes on the Hetero Poz Cruise Retreat each year (See News Briefs on page 16), where he speaks to more than 60 heterosexual individuals, and is able to spend the entire week with them on a cruise. “We think we have it bad in the gay community, but we don’t have it as bad as the heterosexual community with HIV, where they’re terrified of how people treat them in the straight world, too. So it’s not only the gays, it’s the straight people with HIV, especially the women, who have a lot of issues around stigma.”

In order to be able to start to change people’s perceptions, Vergel believes we need to begin with the younger generation. “I think I’m seeing a trend for them to be more open-minded, more accepting of what’s different. Stigma really is a fear of what’s different. Most people stigmatize because they don’t understand certain things, so they’re afraid of them and they discriminate against them.” Vergel thinks HIV is always going to have some stigma associated with it since many of us acquire it through sexual transmission, and because many are stigmatized for being gay.

“But I have seen an openness in that generation—they have straight/gay alliances in most schools, and kids are able to come out earlier than we did. Most of us were in the closet until we were 20-something, so I really think the world’s going to be a better place in 10 or 15 years, when a lot of the older generation that has grown up with a lot of stigma, misconceptions, racism, homophobia, and HIV-phobia are going to be moving a ways back. We have to generate a lot of programs at the college level, the high school level, where we can teach these kids, hey, it’s okay, these people are not evil, HIV doesn’t discriminate, it’s just a virus. I think we’re going to get there, I really think so.

“I may not be alive to see the day,” says Vergel, “But I think the next generation that comes through is going to be more accepting of people who are different, who are not what we call the ‘norm.’ ”

Vergel says he’s very out about his own HIV status and being gay, and that even being an immigrant from South America with a Spanish accent hasn’t caused him to suffer as much stigma as most. “Is it because I am very out about it and I feel actually proud of all the differences I have? Or maybe it’s the fact that I live in a more isolated, bubble kind of world, that doesn’t expose me to people who are really anti-HIV, anti-gay, anti-female, anti-immigrant, and all the other ‘anti’ things we have in the world,” laughs Vergel.

One final thing that Vergel stresses is that it’s really important that all of us, even those who are HIV-negative, deal with the acceptance of aging. “You know, when we look at ourselves in the mirror, we’re not looking like we did 20 years ago. Some of us may still be single and looking for dates, or sex, and some of us may be getting rejected because we are older. For some of us who have been positive for a long time and getting older, we’re not really preparing ourselves. I think we’re in pseudo-denial of the fact that we’re ever going to get a day older because we were not going to be around for that long, or so we thought.”

While Vergel says that we’re never going to be that person we were a few years ago, especially with concerns around lipoatrophy and facial wasting, we have to find ways to love ourselves. “Think of the things we’ve gone through and yet, we’re here, most of us are not falling apart, having productive lives. We’re survivors of a horrible thing that happened, and is still happening, and often we have friends and lovers die around us, and we have to take care of ourselves.”

Vergel was recently involved in an anti-stigma campaign in Houston, and says that early next year they will be holding what he believes to be the area’s first conference focusing specifically on HIV and aging, and bringing in experts to talk about the physical and mental aspects of aging with HIV. “It’s hard,” explains Vergel. “I don’t want to preach about it, because I deal with it too, but somebody needs to look at that. I’d like to see a study, a cohort, observing people who are aging with HIV and what our main issues are.

“I think it’s time.”

For more information on Nelson Vergel and PoWeR, visit www.powerusa.orgFor more information on the Hetero Poz Cruise Retreat, see page 16 or visitwww.positivecruise.com.

Friday, April 03, 2009

FPC NEGOTIATES FOR PATIENT ASSISTANCE


Contact:

Lynda Dee: 410-332-1170



Fair Pricing Coalition

Press Release

FPC NEGOTIATES FOR PATIENT ASSISTANCE AND CO-PAY PROGRAMS

Washington, DC, April 1, 2009 - The Fair Pricing Coalition (FPC), which was founded by the late Martin Delaney of Project Inform, is a national coalition of activists who work on HIV drug pricing issues and who help control drug costs, thereby insuring access for recipients of state AIDS Drug Assistance Programs (ADAPs), Medicare and Medicaid, and patients who are privately insured, underinsured and uninsured.

The FPC has recently negotiated with all major HIV drug manufacturers to require them to institute patient drug co-pay programs. The new drug co-pay programs are a direct result of intense work and negotiations between the FPC and representatives of the pharmaceutical industry.

Most, if not all, HIV pharmaceutical companies already provide some level of patient assistance to individuals who are unable to afford their HIV medications. Several companies have also recently instituted co-pay assistance programs, which may cover all or part of the drug co-pay for many privately insured patients, up to a specified amount, and for a pre-determined period of time, for example, up to one year. Certain restrictions and eligibility requirements apply. For example, ADAP, Medicare and Medicaid patients are ineligible for co-pay programs. Eligibility requirements may vary from program to program. Once eligibility is determined, most companies will then provide patients with a co-pay card which can be presented to a pharmacist or a mail order pharmacy when filling your prescription. Since the FPC expects the launch of new programs and revisions in current programs as negotiations continue, patients should contact or ask their health care providers or pharmacies to contact drug manufacturers directly for updated details on a specific drug.

Jeff Berry, Editor of Positively Aware, Chicago, IL and FPC member states â€Å“In our current economic crisis and with the continued rising costs associated with health care, these new programs offer much needed assistance to people who may have insurance but who can not afford to pay the ever rising cost of their monthly prescription co-pays.”

Below is a brief description of most HIV drug co-pay programs:



Abbott: Positive Partnership PLUS Card. Abbott recently launched a pilot program that expands the Positive Partnership Card. This 12 month program covers Kaletra plus other ARVs and requires no income or co-pay eligibility requirements. Your first out of pocket dollar will be covered up to a maximum of $50 for Kaletra each month. Abbott will also cover another $50 monthly for each additional HIV prescription up to a limit of $100 monthly. The FPC is extremely disappointed that Norvir is currently not part of this program. Visit www.kaletra.com for more information.



Bristol-Myers Squibb (BMS) recently announced that they will be launching a co-pay program in April of 2009. Their program will include Reyataz and Sustiva. More details will be provided as they become available. We hope Atripla, the one pill once a day, which BMS co-manufacturers with Gilead will be covered in the BMS program.

GlaxoSmithKline (GSK): Patient Savings Card. The GSK program is the most patient-friendly, covering the entire amount of all your actual out-of-pocket cost up to a maximum of $100 for each prescription. All GSK HIV drugs are covered, including Combivir, Epivir, Epzicom, Lexiva, Retrovir, Trizivir, and Ziagen. Visit www.mysupportcard.com for more information and to print the card.



Gilead: Truvada Co-pay Assistance Program. Gilead's program covers Truvada, Emtriva, and Viread. This program covers only high co-pays and kicks in only once patients have spent over $50 in out-of-pocket costs and covers a maximum of $200 in co-pays per month. Patients or providers can call toll-free 1-888-358-0398 to receive an eligibility card from Gilead by mail. Atripla is currently not part of this program.



Merck: Unfortunately, Merck does not have a specific insurance co-pay assistance program. However, it does have a patient assistance program for Isentress and Crixivan called â€Å“Support.” If patients need co-pay assistance for Crixivan or Isentress they need to use the Support program. Call 1-800-850-3430, or visit www.isentress.com, click on the site map, and then click Support. Patients have experienced difficulty in accessing the co-pay aspect of this program.

Pfizer: The FPC is also disappointed that Pfizer does not offer co-pay assistance for any of its HIV medications. It does provide reimbursement assistance, appeals assistance, and patient assistance for Selzentry, Viracept and Rescriptor. Pfizer also offers information on obtaining assistance with tropism testing. Call the Pfizer RSVP program at 1-888-327-RSVP (7787).


Tibotec: Tibotec Therapeutics Patient Savings Program. Tibotec covers Prezista and Intelence. This program covers 80% of the amount of your actual out-of-pocket cost up to $100 per drug per month. Visit www.prezista.com/prezista/patient_assistance.html or call toll-free 1-866-961-7169




# # #

Thursday, April 02, 2009

Update on Body Shape Changes and HIV


This Month in HIV: 2009 Update on Body Shape Changes and HIV
A Conversation With Dr. Donald Kotler and Patient Activist Nelson Vergel

April 2009




From TheBody.com


Body shape changes are some of the most frustrating complications of HIV and HIV medications. Whether it's the loss of cheeks or the sudden swollen midsection, people with HIV have been mostly dealing silently with these issues since there are few treatments available. In This Month in HIV, HIV activist and long-time survivor Nelson Vergel leads a discussion with Donald Kotler, M.D., who is an expert on metabolic complications and HIV. They will fill us in on some of the latest updates on this issue.

Nelson Vergel: Hi, Bonnie. Thanks for having me here. And thanks to Dr. Kotler for joining us.

Dr. Kotler, I'd like to start with some basic questions, if you don't mind, to cover the basics about body changes and HIV.

In your opinion, how widespread are body changes in the HIV-positive population? Is there any way that somebody who was recently diagnosed with HIV can know how probable it is that he or she will experience body changes?

Dr. Donald Kotler: That's two questions.

The first one: How frequent are the body shape changes?

The answer is that it depends which shape you're talking about. Some people gain body fat, and others lose body fat. Of the people who gain body fat, for example in the belly, or behind the neck, it's about one-third of patients who have that kind of problem.

In terms of losing body fat and getting really skinny legs, or the skinny face that people notice that's so stigmatizing, in the old days it was almost everybody, and currently it's not many people.

With the change in the antivirals, specifically the stopping of the use of stavudine [d4T, Zerit] and limiting the use of zidovudine [AZT, Retrovir; this drug is also included in Combivir and Trizivir], many fewer people get really thin from lipodystrophy.

Now, the second question: Is there any way that somebody recently diagnosed can avoid these issues?

I gave part of the answer. You can avoid the loss of fat by the choice of medications. Very few people in the United States are taking the medications that will cause body fat loss.

A way of preventing body fat gain was shown about a year and a half ago at the international meeting in Sydney, Australia. Limiting the amount of weight that's gained as people start antivirals will limit the amount of fat that ends up in the belly.1

Nelson Vergel: How do we actually limit the amount of weight that people gain when they start HIV medications?

Dr. Donald Kotler: That's a good question. In the study, which was from Brazil, they use what's called the NCEP [National Cholesterol Education Program] diet. [NCEP was launched in November 1985 by the National Institutes of Health to help reduce illness and death from coronary heart disease in the United States.] It's a healthy diet for somebody with heart disease; it asks people to moderate carbohydrates, decrease fat and consume more fiber. So you tend not to eat things that are so rich and so dense in calories.

It's a standard type of diet for people with heart disease. At least in the study that was presented, people who started their first regimen, plus the diet, gained much less weight -- their cholesterol didn't go up nearly as much and their belly didn't get nearly as big as people who were allowed to eat whatever they wanted.

Nelson Vergel: Dr. Kotler, another issue is the actual word that we use for these changes. People have been using the word "lipodystrophy" for a long time. Is that still a correct word for what's happening in HIV?

Dr. Donald Kotler: Not really, though when you say it, everybody knows what you're talking about. So you could probably get away with it. But lipodystrophy, the classic lipodystrophy, really referred to genetic problems. It was something that people were born with that, as they developed, would show the wasting, would show the thinning of the skin in their face and arms and legs, etc.

The term lipodystrophy with respect to people who are HIV infected is used to mean anything -- fat loss or fat gain, which are not necessarily related, diabetes or high cholesterol, which, once again, may or may not be related to any of the other problems.

We would probably be better off if we were to call fat gain "lipohypertrophy," fat loss "lipoatrophy," and then talk about problems with sugar and fat separately, rather than try to make them all into the one thing.

Nelson Vergel: It is not one thing; they are different syndromes that may happen together or separately.

Dr. Donald Kotler: Right.

Nelson Vergel: You're saying that lipoatrophy -- which is fat loss under the skin in the extremities (e.g., legs), body and face -- is actually not occurring as much in the United States, because we're not using AZT or d4T. But how about fat gain? Is fat gain occurring as much as we used to see it in the '90s, for instance?

Dr. Donald Kotler: Fat gain is, I believe, as common now as it's ever been. I don't think that that's really changed. About one-third of the patients complain of fat gain.

Bonnie Goldman: Are most of the complaints about belly fat? Or are people still seeing fat gain in their neck? Is there one that's more likely?

Dr. Donald Kotler: Belly fat is much more likely. Belly fat is, like I said, a problem in about a third of the patients. Of the people who gain fat behind the neck, probably somewhere between 5 and 10 percent will have a big growth.

Interestingly enough, there are some obese people, who are not HIV infected and not otherwise ill, who actually have small humps. The humps are called buffalo humps, but in HIV, they seem to grow much, much larger.

Nelson Vergel: Dr. Kotler, how does somebody know if they're gaining more weight than normal because they're eating more, or whether it's something related to HIV, or HIV medications?

Some people complain about increased appetite once they start HIV medications. Is the fat gain related to their caloric intake (i.e., how much food people are actually taking in)? Or is there something else -- maybe the fact that their immune system may be getting better?

Dr. Donald Kotler: You know how much weight you can lose when you're sick and then, after you're done being sick, how much weight you can gain, and how fast you can gain weight just when you become healthy?

It turns out that when people start their antivirals, especially when the T cells are down around 200, they are sick. They may not know it. They may not realize it. But they're sick.

If you think about it, antivirals are not appetite stimulants. They're not anabolic agents. So how come people are gaining so much weight? I think the answer to that is that they were sick and had lost weight; so people were thinner than they would normally be and when they take antivirals, it brings them back to a normal weight -- "normal" in the United States is at risk of obesity.

Nelson Vergel: So it is actually better for somebody to start treatment when they're healthier, if they want to avoid any body changes? Is that it?

Dr. Donald Kotler: The literature would say yes. People have looked from the very start as to what makes people lose weight, what makes people gain weight. It turns out that it's a lot of things. Things related to the patient -- for example, family history.

Before you got HIV, if you were 280 pounds, you're probably a lot more likely, when all is said and done, to complain of a big belly than to complain of skinny legs. Whereas if you started out 5'10", 130 pounds, you are probably much more likely to complain that your face looks bad or the veins in your legs are really prominent, than complain of having a big belly.

If everybody in your family is obese, you're probably more likely to have problems on therapy by being obese rather than being skinny.

Nelson Vergel: Have you seen any differences whatsoever with respect to what people start with? Different types of HIV treatments? Are there any data out there that show whether people who start, for instance, on Atripla [efavirenz/tenofovir/FTC] versus Kaletra [lopinavir/ritonavir] or Truvada [tenofovir/FTC] have any differences in body changes?

Dr. Donald Kotler: There are not a lot of data on that, I must say. I don't know that I answered the last question well enough. But, there are many factors that will affect what happens to the patient. These factors can be related to the virus, they can be related to the HIV medication or they can be related to the patient himself, or herself.

For example, family history is related to the patient. Taking a drug like d4T is related to, obviously, the drug. Many people have several of these predisposing factors.

Nelson Vergel: Lipodystrophy (or what we used to call lipodystrophy and are now calling metabolic disorders) also includes increases in triglycerides and cholesterol, especially the bad cholesterol, and decreases in HDL [high-density lipoprotein], the good cholesterol.

Are people with increases in cholesterol and triglycerides more prone to having belly fat increases? Have you seen anything on that subject?

Dr. Donald Kotler: In general, people with a lot of belly fat tend to have increased levels of cholesterol. But there are some medications that, even if given to people who are very thin, will cause cholesterol levels to go up. And there are certain genetic tendencies in people that may make their cholesterol go up high, often when they take antivirals, whether or not they are obese. So you don't have everything or nothing. You can have a big belly and high cholesterol, but you don't necessarily have to have a big belly to have high cholesterol.

Bonnie Goldman: Dr. Kotler, can you specify which medications you are referring to in terms of raising the cholesterol, or raising the fats in the blood?

Dr. Donald Kotler: The one that does it more than any other is ritonavir [Norvir]. It turns out that it depends on how much you take. If you take, for example, the drug Reyataz [atazanavir], you only take one Norvir. If you're taking Kaletra, on the other hand, you take two Norvir. If you take the drug tipranavir [Aptivus], I believe you end up taking four Norvir in a day -- because that's what you need in order to get good drug levels to keep the virus under control. But it turns out that the more Norvir you take, the higher the fat levels are in the blood.

Bonnie Goldman: In Kaletra, you're taking the Norvir within the one pill that you're taking.

Dr. Donald Kotler: Right. You don't take a Norvir tablet. It's inside the Kaletra tablet.

Bonnie Goldman: Many people aren't aware that when they're taking Kaletra, they're also taking Norvir.

Nelson Vergel: Dr. Kotler, another assumption people make -- and I think even some clinicians out there -- is that if you treat high cholesterol with a cholesterol-lowering drug, or anything else that treats it, you will tend to decrease belly fat. Is that a right assumption? Are there any data to substantiate that?

Dr. Donald Kotler: No. It's the other way around. If you have a big belly and high cholesterol, and you make the belly small, the cholesterol will go down.

But if you have a big belly and high cholesterol, and you take a drug to lower the cholesterol, it may not do anything to your belly.

Nelson Vergel: Are there any treatments right now for the belly fat gain?

Dr. Donald Kotler: No. There are no treatments that are approved by the FDA [U.S. Food and Drug Administration]. Obviously, losing weight does something, although many people will say it doesn't do nearly as much as they want it to. You try to lose weight to lose your belly, but then you lose your butt, or your face looks worse and your belly doesn't change all that much.

Nelson Vergel: How about exercise?

Dr. Donald Kotler: Some people do that. Exercise will do it. The exercise that tends to do it is more resistance training exercise (i.e., lifting) than aerobics, surprisingly enough.

Nelson Vergel: Some people are actually afraid of aerobics because of fat loss.

Dr. Donald Kotler: Exactly. There are other people who have shown that some of the antidiabetic medicines, such as Glucophage [metformin], have been shown to decrease belly size.

There were several studies that looked at the drug growth hormone. Growth hormone did significantly lower belly size, but the FDA didn't approve it, likely because they were not happy with the side effect profile. They thought it was too toxic a drug.

Now, a month and a half ago, there was a meeting in London, the 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. At that meeting, two other treatments were talked about. One was a drug called IGF-1 [insulin-like growth factor 1], or IGF-1 combined to a binding protein.

It's what growth hormone causes to happen. But here, rather than using growth hormone, they use the IGF-1. And rather than this worsening toxicity, worsening blood sugar, it actually made it better. It also caused an anabolic effect: lean mass went up and the amount of fat in the trunk went down. But it didn't really lower it as much as had been seen before with growth hormone. But it was a little, tiny study, just to show that it could work.

In addition, there's a drug called tesamorelin, which [acts as a] growth hormone-releasing factor. So when you give tesamorelin, you get a growth hormone-like effect and that also causes belly fat to go down. It doesn't cause glucose to get worse, like growth hormone does.

At this same meeting in London, Julian Falutz from Montréal looked at the two studies of this drug, tesamorelin, to see if it mattered what kind of antivirals are used.2 Does it matter if someone is taking protease inhibitors or the non-nucleosides? Does it matter whether someone is taking Kaletra or Sustiva [efavirenz, Stocrin]? It turns out that it doesn't matter. The drug tesamorelin will cause body fat to decrease. It will cause belly fat to decrease, no matter what your drug is.

Nelson Vergel: That drug is not approved yet?

Dr. Donald Kotler: The drug is not approved yet. But there have been several studies that have shown its benefit -- three, actually. I believe the FDA is looking at it now or, if not now, very, very soon. [Click here for more on tesamorelin.]

Nelson Vergel: If you were an HIV-positive patient, right now, in 2009, and you had problems with belly fat, what would you do? Just diet and exercise? Is that all we have?

Dr. Donald Kotler: Right now diet and exercise are the best hope. I would not treat with an antidiabetic medicine in the absence of diabetes.

Nelson Vergel: So you're not sure whether, for instance, Glucophage, which is an antidiabetic drug, would do anything for somebody who is experiencing belly fat gain.

Dr. Donald Kotler: Let's say you have to wear a size 40 pants, or keep your pants so low that your belly hangs over in a not very nice looking way, and you start taking Glucophage. Your waist will probably go from 40 to 39. You wouldn't go down to a 33, or a 32, or even a 34. The effect of Glucophage is really tiny.

When it was used at high doses, the effect of growth hormone was more like two or three inches. You'd go down to a 37 or a 36 waist. But it was real toxic and caused a lot of problems. Drugs like tesamorelin cause your waistline to decrease only an inch or so.

Nelson Vergel: The unfortunate thing, in my point of view, is that we haven't really seen combinations of therapy. For instance, researchers have not looked at exercise plus either the growth hormone-releasing factor or Glucophage. As an activist, I think I'm also a little frustrated that there are no real guidelines on the nutritional aspects of this problem. Like you said, nutrition and dieting. Where do we send people when they want information about what to eat? Do you recommend just a Mediterranean diet? Anything specific?

Dr. Donald Kotler: A Mediterranean diet would work well. People tend to do better with low-carbohydrate diets, as opposed to low-fat diets whether they are HIV positive or HIV negative. For people who don't know what a Mediterranean diet is, it is olive oil, nuts, very low in highly saturated fats, more fish and less meat. [Click here for more details on what a Mediterranean diet is.] But there has been very little data published on it, in terms of its effects in HIV.

Nelson Vergel: That brings me to the next question. If you had all the money in the world, what would be your main research project, when it comes to the area of body shape disorders in HIV?

I'm interested in your view since you both see patients and do research -- which is a good thing since many researchers don't actually see patients.

Dr. Donald Kotler: That's an easy question. If I had all the money in the world, I would study everything. But if I could only do one thing, what would I do? It would be a comprehensive program in which I wouldn't be looking for one treatment, but rather, I would use the combination.

It would be diet and it would be exercise and it would be medication. Our laboratory presented a study at the lipodystrophy meeting in London, in which we compared diet and exercise to diet and exercise plus the drug rosiglitazone [Avandia], or simply rosiglitazone alone. Rosiglitazone is an insulin-sensitizing agent; it's an antidiabetic agent.

The question we asked is: If we treat an HIV-positive person with big-belly lipodystrophy and an HIV-negative person who has a big-belly metabolic syndrome the same, would they respond the same?

If I got somebody who has HIV to lose 15 pounds and get into good shape, would his or her insulin resistance change the same as someone who is HIV negative?

Although we didn't have enough people in the study to be able to be absolutely confident of the results, it seemed that the two groups responded pretty much the same.

The average weight loss we got was about 15 pounds. The changes in an HIV-positive and in an HIV-negative person were really pretty much the same not only in the belly, but also in things like cholesterol and the special types of good cholesterol and bad cholesterol.

It looked like HIV didn't really influence it very much. So in the absence of any other information, I would treat an HIV-positive person the same as I would treat an HIV-negative person with metabolic syndrome. The best treatment is to treat it all -- not looking for one magic pill, but instead getting people to eat less, getting people to eat smarter and getting people to exercise more. If there is high cholesterol, bring it down. If the triglycerides and other types of fat are high, bring them down.

If the usual medicines don't work, well, then you try other things, like fish oil (omega-3 fatty acid) or niacin. There are a number of these new medicines that have been tried in HIV. They seem to work about as well in HIV as in non-HIV; it's not so different.

So I think that the optimal way to do it is a whole integrated program.

Bonnie Goldman: But don't you think that many patients around the country don't have a physician that they could turn to who may have this kind of very understanding point of view?

Dr. Donald Kotler: Maybe not a lot of private doctors, but there are a lot of clinics that are putting together metabolic clinics that are putting together expertise to look at having a cardiologist or an endocrinologist treating diabetes go into the HIV clinics to treat people.

You're right. It's not really fully integrated. But I think that would be the best.

Nelson Vergel: As an activist, I think the community also has to take an active role in advocating for things like this. In Houston, Texas, we have a non-profit where we provide exercise and dieticians looking at people's diets and trainers. Yet in the past five years, we haven't been able to duplicate these kinds of programs anywhere else because of money. Money and funding are really tight lately, especially in HIV. People sometimes don't even have the money to get the treatments, the HIV medications, which are basic. So it's a battle.

My next question -- which is really relating to this -- is: How do we get insurance companies or Medicare/Medicaid -- other systems that pay for medication -- how do we get them to accept that body changes in HIV are not a cosmetic issue, per se. It's something that not only affects people's self-esteem, anxiety and depression, and quality of life, but it may actually be something that also affects their survival, eventually.

That's where we have the most challenge right now. How do we shift from perceiving this as a cosmetic issue -- shifting third-party payers, insurance companies, to see it as a clinical problem?

Dr. Donald Kotler: It's not really a medical question. It's a question for activists. I think that the answer is activism. My suggestion would be to push it as a comprehensive care program, rather than a reimbursement for drug X. Because in fact some of the treatments are so costly that I don't know that I would be happy paying for the treatment in somebody who is not watching their diet or someone who would not consider doing exercise. Or even -- which is what's happened before and which is what I think limited it before -- you don't necessarily even look at the results of what you're doing; that it's really considered more of an entitlement to get the prescription, as opposed to having somebody measure you, work out your risk, give you some treatment and follow up. If you're not responding the way you should, look to find out why. Sometimes the medicine is not even being taken.

I think it's important to accept the fact that there's not a magic bullet, but there are a lot of things that you can do to help yourself. I think that the activists should really push on that.

Nelson Vergel: That's my main goal. I just wanted to summarize it, because some people may be so concerned about this discussion, and they're considering going on HIV medications for the first time.

The fact is that we're not experiencing as many problems metabolically right now, compared to 10 years ago. Is that a fair statement, in your point of view? Should people be really concerned before they start treatment?

Dr. Donald Kotler: The one thing that doesn't seem to have changed is that if people gain weight, they may get a big belly.

On the other hand, the diabetes that used to be seen, especially with Crixivan [indinavir], we don't see much of that anymore. There may be more diabetes that comes with Zerit or AZT, but for people taking the newer medicines, we don't tend to see that nearly as much.

The lipoatrophy -- the skinny face, the skinny butt and the really skinny legs -- if we see somebody now who has that, it's somebody who has been treated with HIV medications for a long time, and has had that for years.

With the new HIV medicines, it doesn't tend to happen that much anymore. The high triglycerides and high cholesterol: We still see some of it, although much of it occurs in people who are genetically predisposed to it.

The new medicines, like the integrase inhibitor Isentress [raltegravir, MK-0518], the CCR5 antagonist Selzentry [maraviroc, Celsentri] or the entry inhibitor Fuzeon [enfuvirtide, T-20], don't seem to cause any of these problems.

I think that people now are a lot less likely to develop these changes than they were in the past. It may be that if people are really careful about trying to prevent weight gain and eating very healthily at the time they start their antivirals, they may be much less likely to get it. On the other hand, if somebody weighed 280 before any of this happened and you make them healthy again, they are, as likely as not, going to go back to a weight of 280.

Nelson Vergel: Are some of these changes related to aging, or are they really accelerated aging by HIV and HIV medications?

Doctors are also saying to patients, "Well, don't complain. You really are healthy. It's just that you are getting older, too."

Dr. Donald Kotler: They are steady changes. But if you look at HIV-negative people, even though the changes are pretty continuous, when do people start really seeing the belly fat? And when do men start losing their butt, even if they're not HIV infected? It seems to be somewhere between ages 45 to 50. At that point, jeans fit differently. They are no longer tight in the thighs and loose in the waist; it's the other way around.

Nelson Vergel: There are also some hormonal changes, too, right?

Dr. Donald Kotler: Right. People's own growth hormones go down. People's own testosterone levels go down.

Nelson Vergel: Even thyroid. We're seeing some reports on thyroid dysfunction in some patients, too, right?

Dr. Donald Kotler: That's kind of an immune reconstitution problem, though. You'll get laboratory abnormalities. It really causes your thyroid to get so bad that you need hormone replacement.

Nelson Vergel: So it is good for patients who are experiencing some of these changes to at least get some of their hormones checked and talk to their doctors about it, right?

Dr. Donald Kotler: Absolutely. Women tend to have more problems with thyroid than men, so it's especially important in a woman, because she might develop a thyroid problem totally independent of HIV. Not everything that happens to people who are HIV positive is really HIV related.

Nelson Vergel: Dr. Kotler, one last question from my side. We're seeing some reports on decreases in bone density. Is that something that you see in your practice? I'm not even talking about research. I'm talking about your practice. You see a lot of patients in New York. You've been around since the '80s. I think you're probably one of the leaders in metabolic disorders.

In your practice, are you starting to see any bone-related fractures or any bone-related problems?

Dr. Donald Kotler: Yes, I've been seeing this for a long time. In fact, the bones that I've seen break most commonly, being in the middle of a city, are bones in the feet in people who run on treadmills. I don't see a whole lot of broken hips, broken ribs or crushed vertebrae. But I've seen people break bones in their feet, simply by the pounding.

At the meeting in London, there were a couple of interesting talks about bone. It's known that thin bones, brittle bones, are very common. Whereas most people blame antivirals, you can also see it in HIV-positive people who are untreated. So HIV-positive, treatment-naive people also may have thinned, decalcified bones. If that's the case, well, then it can't just be due to drugs!

There are two possibilities. Actually, the one possibility that many researchers are leaning towards is that when you're sick, you have inflammation. Inflammation tends to cause bone to break down.

Just like somebody who has chronic bronchitis from cigarette smoking and on that basis gets brittle bones, somebody can have a chronic infection with HIV and get brittle bones. It was felt that it was just the inflammation.

However, a group from Ireland exposed growing bone cells to HIV in serum -- either a low viral load or a high viral load or a negative viral load -- and showed that, when you exposed the cells to HIV, the bone cells tended to turn into fat cells. Bone cells and fat cells are related. So there may be something about HIV itself that tends to shut off the calcium being laid down in the bone. That was brand new information that hadn't been seen before.

There was another study, though, and this was really very hard to understand. It was related to the SMART study. You remember the SMART study?3 In that study, patients either stayed on therapy or, when their T cells went up, they stopped therapy, and then when their T cells went down, they started treatment again. It was a big study of a couple thousand people. [Click here to read more about the SMART study and treatment interruptions.]

Two hundred seventy-five of the people in the study actually had bone density studies done, either when they were on continuous therapy, or starting and stopping.

In fact, in that study, the people who stayed on therapy tended to have more bone problems than those who started and stopped. The author said that is not a reason to start and stop. So don't take that as a reason. But the people who were on therapy and didn't stop were more likely to have fractures and, when they were followed over, I believe, two years, they were more likely to lose calcium in their bones than the people who did start and stop.

That was a surprise finding, as almost everything out of the SMART study is. Nobody's really sure what to make of it, other than, as we move forward, we probably should be concentrating on bone density and making sure that we don't allow our patients to get to the point where they are likely to have fractures.

Nelson Vergel: That's definitely a problem I'm seeing. Very few doctors are prescribing bone scans, DXA [dual energy X-ray absorptiometry] scans, before therapy or once every few years to follow up on patients even if they don't think it's a problem; it's just that it's really not part of standard of care. That's another activist issue.

Dr. Donald Kotler: The activist issue is reimbursement.

Nelson Vergel: Those who stayed on continuous therapy in the SMART study also had fewer problems with heart attacks and cardiovascular disease, right?

Dr. Donald Kotler: Right ... as well as other endpoints. The people who started and stopped are more likely to have problems with liver disease and are more likely to have problems with tumors. Starting and stopping has turned out not to be healthy.

Nelson Vergel: Any other questions, Bonnie? I think Dr. Kotler has been extremely helpful in clarifying some of the questions the community has.

Bonnie Goldman: If you have bone density issues, is it related to fat accumulation or fat wasting? Or are they all kind of the same phenomena?

Dr. Donald Kotler: Sort of, because they tend to be found in the same people. But no, I don't know how they are necessarily related in terms of the cause.

Bonnie Goldman: It sounds like there are hints of a lack of calcium in patients. Would this mean that it's a good idea to take calcium supplements to prevent bone density loss?

Dr. Donald Kotler: I don't know. I don't know if taking calcium supplements prevents it. That's the problem.

Nelson Vergel: Or exercise.

Dr. Donald Kotler: You should avoid vitamin deficiency. You should avoid eating too little calcium. That's mainly a problem in people who have trouble with milk and dairy. If you're lactose intolerant, you tend to eat less calcium than if you are not lactose intolerant.

Somebody who is at risk for bone loss should make sure they are taking enough calcium in their diet, should make sure there's at least enough vitamin D in their diet. I don't know, though, that just by taking an extra two vitamins everything will be cool. I just don't know that. I think that you would be better off having your bone density checked.

Certainly, if your bone density is low and you take the regular bone density medicines, like the kind that you see on TV, they do work.

I'm not sure how well vitamin D and calcium work. But the kinds of drugs, what are called bisphosphonates, that you either take every day, every week or every month, they do cause bone density to rise.

Bonnie Goldman: Do you see a lot of people having metabolic complication myths? They think it's due to all the protease inhibitors, or they think it's due to all antiretrovirals. Are there myths that we need broken?

Dr. Donald Kotler: I don't know. Patients tend, if they believe the doctor, to believe what the doctor tells them. So if there's a myth, it's probably the myth of the doctor. This whole idea that protease inhibitors caused everything didn't come from the patients. It came from the doctors. We had it wrong. We tend to have it wrong a lot, unfortunately.

Bonnie Goldman: I think that's one of the reasons that these kinds of complications -- bone, metabolic complications and body shape changes -- are so difficult. Because it's an ongoing understanding. And we don't know that much about this.

Dr. Donald Kotler: There's another part of it, though. It's that we're looking so hard at T cells, or viral load, that we just tend to forget about the rest. We're working so hard to make sure that people don't get cytomegalovirus (CMV), or toxoplasmosis, and die. When they get better and they're not going to die of the AIDS things, we can either say that's fine or ask what else would it be. As HIV docs we're not built to be worried about people's prostates or breast self-exams. We were aiming towards fighting pneumocystis pneumonia [PCP], CMV and all the rest. So we have had to retrain ourselves to be primary care physicians, to look at things that would happen to somebody who doesn't have a killer disease.

What happens to people without a killer disease? You either get cancer or heart disease. Or you develop Alzheimer's disease, or bad kidney disease, or all the other stuff. We're just coming around as doctors to realize that. Patients also have to come around.

Probably the best example of where patients and doctors have been caught short has to do with cigarette smoking. I knew it. If I had a patient who was dying of AIDS in 1985, I didn't bother much about them smoking cigarettes. What for? Now, it turns out that lung cancer is really common in HIV, and has nothing to do with HIV, it seems, and has everything to do with cigarette smoking.

So only lately have doctors like myself said, "Look, you're not going to die of AIDS. Why would you go through all that and then allow yourself to die of lung cancer? How could you be so crazy?" We're just getting around to that now.

Bonnie Goldman: You need to have a historic point of view to understand this whole issue, and how we came to the point where we're now dealing with this.

Dr. Donald Kotler: There's nobody to blame, because it's success. But if we want real success, it's not only not allowing somebody to die of AIDS, it's not allowing anybody to die before their time of anything. Drug overdose, as well.

Bonnie Goldman: And also dealing with quality-of-life issues -- you may live a long life, but you might have this belly that embarrasses you.

Nelson Vergel: Or facial wasting, or fatigue, or many other issues. One more question that I just thought of related to this talk about HIV doctors training themselves to be primary care physicians and treating people that are aging with HIV and who are showing up with some of these metabolic problems: Are there any Web sites, any groups, where guidelines are posted for doctors when it comes to metabolic disorders? One place, one document? Anything that doctors who are starting to treat HIV nowadays can go to to train themselves?

Dr. Donald Kotler: If you google "HIV metabolic guidelines," there have been several from the International Association of Physicians in AIDS Care, and from the International AIDS Society-USA. I believe that the Europeans also have one. There are some guidelines that are written. The early guidelines were not great. They would say, "In the absence of information, you probably should treat diabetes in HIV like you treat diabetes in non-HIV." For high cholesterol, or high triglycerides, as well, you should consider the medications. After that, you should treat just like you would treat anybody else.

I think the major point is that you don't ignore something that's bad. In the past, we ignored cigarette smoking, because we were worried that people were going to die of CMV.

Now we shouldn't ignore cigarette smoking. We shouldn't ignore high cholesterol, and we shouldn't ignore diabetes. We shouldn't ignore excess weight gain. We shouldn't ignore any of it.

Bonnie Goldman: So, success has allowed us to focus on these other details.

Dr. Donald Kotler: Yes, and those who are successful have more work to do.

Nelson Vergel: I also remind patients that HIV medications may have some side effects, but the worst side effect is leaving HIV untreated. I always say that, because sometimes we lose perspective and forget that these medications have kept a lot of us alive for 20-plus years. Sometimes the new guys and girls that are coming through with treatment are so afraid. I remind them that leaving HIV untreated can cause more problems than any side effects they may have in the future that can be treated by a good doctor.

Dr. Donald Kotler: I was in clinic today and saw a 24-year-old girl with a CD4 of 5, who had herpes around the rectum and around the vagina, who was being treated for MAC [Mycobacterium avium complex] infection in the liver, who has a huge liver, and who also probably has CMV. She had lost 70 pounds. She doesn't leave the house. She feels miserable. There's no reason for it.

Nelson Vergel: She got to a good doctor, though.

Dr. Donald Kotler: She's at a good clinic.

Nelson Vergel: A good clinic, that's lifesaving. Anything else, Bonnie? Dr. Kotler has been great.

Bonnie Goldman: I think this is really great, and hopefully it explains some of the phenomena that people have been experiencing. Maybe it will motivate a lot of people to go on a diet, do some exercise and take charge of their health in that way, while waiting for other treatments or other understanding of metabolic complications.

Nelson Vergel: Hopefully, we'll bother Dr. Kotler in the future to give us more details about any progress in this field, too. So, thank you.

Bonnie Goldman: Thank you so much for taking the time to talk with us. Thank you, Nelson, for joining us and for leading the conversation. I really appreciate that.

Nelson Vergel: Thanks a lot for having us! We'll talk to each other soon, I hope.

We want to know what you think of this podcast! Click here to take our quick survey!




References
Lazzaretti R, Pinto-Ribeiro J, Kummer R, Polanczyk C, Sprinz E. Dietary intervention when starting HAART prevents the increase in lipids independently of drug regimen: a randomized trial. In: Program and abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract WEAB303.
Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. December 6, 2007;357(23):2359-2370.
Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. November 30, 2006;355(22):2283-2296.
For more information on facial wasting, check out our lipoatrophy resource center.

Click here to read Mark King's latest blog about treatment for facial wasting.




You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art51106.html

General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.

Support PoWeR

Program For Wellness Restoration

Health News

Blog Archive

The Cure of HIV is Possible in Our Lifetime